{
    "organizations": [],
    "uuid": "d75a2b9b6b120cbefbf0d4d96e4151c2a13b1513",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-arcus-biosciences-now-sees-ipo-of/brief-arcus-biosciences-now-sees-ipo-of-up-to-7-1-mln-shares-priced-between-13-and-15-per-share-idUSFWN1QN0E4",
    "ord_in_thread": 0,
    "title": "BRIEF-Arcus Biosciences ‍​Now Sees IPO Of Up To 7.1 Mln Shares Priced Between $13 And $15 Per Share",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) -\n* ARCUS BIOSCIENCES INC ‍​NOW SEES IPO OF UP TO 7.1 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $13.00 AND $15.00 PER SHARE - SEC FILING\n* ARCUS BIOSCIENCES INC SAYS INTENDS TO USE ABOUT $55.0 MILLION OF IPO PROCEEDS TO FUND CLINICAL DEVELOPMENT OF AB928 AND AB122 Source text: ( bit.ly/2oQRjdU )\n ",
    "published": "2018-03-05T19:46:00.000+02:00",
    "crawled": "2018-03-06T22:26:13.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "arcus",
        "bioscience",
        "inc",
        "see",
        "ipo",
        "million",
        "share",
        "common",
        "stock",
        "priced",
        "per",
        "share",
        "sec",
        "filing",
        "arcus",
        "bioscience",
        "inc",
        "say",
        "intends",
        "use",
        "million",
        "ipo",
        "proceeds",
        "fund",
        "clinical",
        "development",
        "ab928",
        "ab122",
        "source",
        "text"
    ]
}